SB5, an adalimumab biosimilar approved in the US, is showing to be safe and effective for patients with psoriasis in the long term, according to a study from the UK and Ireland.

For moderate to severe cases, systemic biologics work to ... together into the newer novel agents class that are indicated for all levels of severity in psoriasis. Unlike traditional topical ...

and treatment trials with agents also used for diseases such as rheumatoid arthritis (RA) and psoriasis. Biological agents, especially the antitumour necrosis factors, have demonstrated significant ...

In particular, the availability of new, biological antitumour necrosis factor α therapies have allowed further insight into the immunopathology of psoriasis and PsA ... PsA patients were treated with ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment   TOKYO and CAMBRIDGE, Mass., Jan. 26, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: ...

Investigative therapies to treat moderate to severe plaque psoriasis in clinical trials include several orally administered ...

Biosimilar SB17 demonstrated clinical biosimilarity to reference ustekinumab after switching among patients with psoriasis ...

Jan. 20, 2025 — People with the skin condition psoriasis often have invisible inflammation in the small intestine with an increased propensity for 'leaky gut', according to new research.

Plaque Psoriasis BURLINGAME, CA, UNITED STATES, January 27, 2025 /EINPresswire / -- The worldwide Plaque Psoriasis <a target=_blank href=h ...

A new study published in the Archives of Dermatological Research found that patients with psoriasis who were receiving biologic treatment, are at a high risk of acquiring metabolic ...

THE RELATIONSHIP between biologic therapies and the risk of major adverse cardiovascular events (MACEs) and venous ...